The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.36
Bid: 2.35
Ask: 2.41
Change: 0.23 (10.70%)
Spread: 0.06 (2.553%)
Open: 2.20
High: 2.45
Low: 2.20
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Share Options

19 Mar 2024 07:00

RNS Number : 3189H
Immupharma PLC
19 March 2024
 

19 March 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Grant of Share Options

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.

 

The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting conditions which reflect the corporate objective of restoring and enhancing shareholder value as follows:

 

Tim McCarthy 8,000,000 share options (exercise price £0.02)

Tim Franklin 6,500,000 share options (exercise price £0.02)

Sebastien Goudreau 5,000,000 share options (exercise price £0.02)

 

In addition, 5,500,000 unapproved Share Options have been awarded to other employees/contractors with the same performance conditions.

 

Share Option Period: All Share Options are valid for 10 years from the date of issue.

 

Time and Performance Conditions:

 

All Share Options will vest at the latter of:

 

· When the Company has completed a new commercial deal of significant value; and

· 3 years from the date of issue

The Remuneration Committee will determine when these conditions have been met.

 

ENDS

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 650 3650

 

 

+44 (0) 1483 413500

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor?, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Tim McCarthy

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 1p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

Grant of share options over new Ordinary Shares

c)

 

Price(s) and volume(s)

 

Exercise Price

Volume

2 pence

8,000,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

e)

Date of the transaction

18 March 2024

f)

Place of the transaction

n/a

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Tim Franklin

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 1p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

Grant of share options over new Ordinary Shares

c)

 

Price(s) and volume(s)

 

Exercise Price

Volume

2 pence

6,500,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

e)

Date of the transaction

18 March 2024

f)

Place of the transaction

n/a

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Sebastien Goudreau

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 1p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

Grant of share options over new Ordinary Shares

c)

 

Price(s) and volume(s)

 

Exercise Price

Volume

2 pence

5,000,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

e)

Date of the transaction

18 March 2024

f)

Place of the transaction

n/a

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBCGDXSBBDGSI
Date   Source Headline
30th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSBoard Appointment
28th Jun 202112:27 pmRNS2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28th Jun 202111:03 amRNS2021 RESULT OF ANNUAL GENERAL MEETING
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUpdate: Lupzuor™ PK study
2nd Jun 20217:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20217:00 amRNSDirector Retirement
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
9th Feb 20217:00 amRNSUpdate- scheduled Phase 3 trials in lupus patients
18th Jan 20217:00 amRNSAppointment of Company Secretary
4th Jan 20217:00 amRNSHolding(s) in Company
2nd Dec 20207:00 amRNSIMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30th Nov 20207:00 amRNSTotal Share Capital Notification
26th Nov 20207:00 amRNSGrant of Share Options & PDMR dealing
24th Nov 20207:00 amRNSConversion of Convertible Security
23rd Nov 20207:00 amRNSConversion of Convertible Security
20th Nov 20207:00 amRNSUpdate : FDA confirms 4 Dec for Type ‘A’ meeting
18th Nov 20207:00 amRNSTotal Share Capital Notification - Replacement
10th Nov 20207:00 amRNSUpdate on submission to the FDA
30th Sep 20207:01 amRNSTotal Share Capital Notification
30th Sep 20207:00 amRNSInterim Results
29th Sep 20207:00 amRNSShare Subscription into Incanthera plc
22nd Sep 20207:00 amRNSRepayment of Convertible Security
11th Sep 20207:59 amRNSUpdate on submission to the FDA
10th Sep 202010:59 amRNSConversion of Convertible Security
9th Sep 20201:45 pmRNSConversion of Convertible Security
8th Sep 20203:49 pmRNSHolding(s) in Company
8th Sep 20209:00 amRNSDirector/PDMR Shareholding / TR -1
7th Sep 20207:02 amRNSPlacing - update; related party transaction)
3rd Sep 20207:00 amRNSConversion of Convertible Security
2nd Sep 20207:00 amRNSPlacing to raise £6.5 million
1st Sep 20207:00 amRNSHolding(s) in Company
27th Jul 20207:00 amRNSFDA submission for Special Protocol Assessment
18th Jun 202011:31 amRNS2020 AGM – ALL RESOLUTIONS PASSED
16th Jun 20207:00 amRNSTotal Share Capital Notification
11th Jun 202012:00 pmRNSTR-1 Notification of major holdings
11th Jun 20207:00 amRNSSTRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
5th Jun 20207:00 amRNSChange of Registered Office Address
2nd Jun 20207:00 amRNSNotification of Change of AGM Venue
21st May 20207:00 amRNSNotice of AGM and posting of Report & Accounts
18th May 20201:45 pmRNSTR-1: Notification of major holdings
14th May 20207:00 amRNSEfforts in fight vs Covid-19 with Lupuzor; Ureka
30th Apr 20209:57 amRNSAudited Report & Accounts published on website

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.